SAN DIEGO, Feb. 24, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that data to be presented at the 2015 ASCO Genitourinary Symposium demonstrates that its Decipher® Prostate Cancer Classifier was able to accurately identify patients with a high probability of metastasis-free survival despite being identified as high risk by standard risk assessment tools. Additionally, researchers showed that Decipher was able to identify which men who historically have been classified as high risk could safely delay radiation treatment and avoid adverse side-effects. The Decipher® Prostate Cancer Classifier is a genomic test capable of predicting the probability of developing metastatic prostate cancer following a prostatectomy. Three clinical validation studies for Decipher will be presented on February 26 at the 2015 ASCO Genitourinary Symposium from 11:30 a.m. to 1:00 p.m. ET in Orlando, FL.
In a new, prospective, blinded evaluation of 260 men classified as intermediate and high risk by NCCN guidelines and treated with radical prostatectomy at Johns Hopkins Medical Institute, Decipher demonstrated that it is an accurate and independent predictor of metastatic disease within 10 years of surgery in a cohort of patients who received no radiation therapy. This latest validation study for Decipher provides additional evidence that the test can identify low risk men based on genomics who may be managed conservatively after surgery. The study also evaluated Decipher and 33 other published prognostic signatures and showed Decipher to be the top predictor of postoperative metastasis. These findings were echoed in another cohort of node-negative high risk men treated at the Cleveland Clinic. In a separate study performed in conjunction with Thomas Jefferson University and Mayo Clinic and published this month in the Journal of Clinical Oncology, Decipher was shown to augment decision making for men considering adjuvant radiation therapy after radiation therapy. All three studies will be presented this week during the 2015 ASCO Genitourinary Symposium.
The studies being presented are:
The Decipher® Prostate Cancer Classifier is a highly validated and commercially available genomic test for men with intermediate and high risk prostate cancer. Decipher predicts cancer aggressiveness by looking for a unique genomic signature comprised of a validated series of biomarkers associated with metastatic disease. Adding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors. Clinical studies from leading cancer centers published in over a dozen medical journals demonstrate that Decipher can accurately predict metastatic disease, which men may benefit from radiation therapy following prostate surgery, and can lead to significant cost-savings for healthcare systems. Decipher was developed in partnership with the Mayo Clinic.
Decipher is covered by Medicare and multiple private insurance plans and is available to eligible US patients through their physicians.
Learn more at: www.DecipherTest.com.
About GenomeDx Biosciences
GenomeDx Biosciences is focused on transforming cancer patient care by putting usable genomic information in the hands of patients and their physicians. GenomeDx is developing and commercializing Decipher®, a highly validated genomic test for predicting metastatic disease in men with prostate cancer. In partnership with leading medical centers, the company has assembled the largest genomic catalogue of prostate cancer tumors in the world, representing billions of data points and more than 20 years of prostate cancer research expertise. Using advanced cloud-based bioinformatics, GenomeDx mines the genomic data to develop proprietary tests that address key clinical questions in cancer patient management. GenomeDx has partnered to share genomic data with leading clinician-scientists worldwide to collaboratively enrich the knowledge and understanding of urologic cancers for the goal of improving global cancer patient care. GenomeDx is based in San Diego, California and Vancouver, British Columbia.
Learn more at www.genomedx.com.
Media Contact:Ian StoneCanale [email protected]
Advertisement
In a new, prospective, blinded evaluation of 260 men classified as intermediate and high risk by NCCN guidelines and treated with radical prostatectomy at Johns Hopkins Medical Institute, Decipher demonstrated that it is an accurate and independent predictor of metastatic disease within 10 years of surgery in a cohort of patients who received no radiation therapy. This latest validation study for Decipher provides additional evidence that the test can identify low risk men based on genomics who may be managed conservatively after surgery. The study also evaluated Decipher and 33 other published prognostic signatures and showed Decipher to be the top predictor of postoperative metastasis. These findings were echoed in another cohort of node-negative high risk men treated at the Cleveland Clinic. In a separate study performed in conjunction with Thomas Jefferson University and Mayo Clinic and published this month in the Journal of Clinical Oncology, Decipher was shown to augment decision making for men considering adjuvant radiation therapy after radiation therapy. All three studies will be presented this week during the 2015 ASCO Genitourinary Symposium.
Advertisement
The studies being presented are:
- Abstract #154: "A genomic classifier to improve prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy" by Eric A. Klein, et al. (Display board G16)
- Abstract #168: "A genomic classifier to identify men with adverse pathology post radical prostatectomy who benefit from adjuvant radiation therapy" by Robert B. Den, et al. (Display board H4)
- Abstract #173: "Validation of the Decipher prostate cancer classifier in intermediate to high-risk men treated with radical prostatectomy but without additional therapy upon PSA rise" by Ashley Ross, et al. (Display board H9)
The Decipher® Prostate Cancer Classifier is a highly validated and commercially available genomic test for men with intermediate and high risk prostate cancer. Decipher predicts cancer aggressiveness by looking for a unique genomic signature comprised of a validated series of biomarkers associated with metastatic disease. Adding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors. Clinical studies from leading cancer centers published in over a dozen medical journals demonstrate that Decipher can accurately predict metastatic disease, which men may benefit from radiation therapy following prostate surgery, and can lead to significant cost-savings for healthcare systems. Decipher was developed in partnership with the Mayo Clinic.
Decipher is covered by Medicare and multiple private insurance plans and is available to eligible US patients through their physicians.
Learn more at: www.DecipherTest.com.
About GenomeDx Biosciences
GenomeDx Biosciences is focused on transforming cancer patient care by putting usable genomic information in the hands of patients and their physicians. GenomeDx is developing and commercializing Decipher®, a highly validated genomic test for predicting metastatic disease in men with prostate cancer. In partnership with leading medical centers, the company has assembled the largest genomic catalogue of prostate cancer tumors in the world, representing billions of data points and more than 20 years of prostate cancer research expertise. Using advanced cloud-based bioinformatics, GenomeDx mines the genomic data to develop proprietary tests that address key clinical questions in cancer patient management. GenomeDx has partnered to share genomic data with leading clinician-scientists worldwide to collaboratively enrich the knowledge and understanding of urologic cancers for the goal of improving global cancer patient care. GenomeDx is based in San Diego, California and Vancouver, British Columbia.
Learn more at www.genomedx.com.
Media Contact:Ian StoneCanale [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/data-presented-at-2015-asco-genitourinary-symposium-compares-validates-and-demonstrates-utility-for-genomedxs-decipher-test-300040137.html
SOURCE GenomeDx Biosciences
